Testicular Neoplasms clinical trials
The registry lists 295 studies for Testicular Neoplasms across more than 10 countries. 51 are recruiting or about to start. 84 of them are mainly about Testicular Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its 2 narrower conditions too, such as Testicular Germ Cell Tumor: 310 studies, 57 open.
Get an email when these change. Save the Testicular Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
National Cancer Institute (NCI) (17) · Memorial Sloan Kettering Cancer Center (15) · Fred Hutchinson Cancer Center (13) · University Medical Center Groningen (11) · Children's Oncology Group (11) · National Institutes of Health Clinical Center (CC) (5) · University of Southern California (5) · City of Hope Medical Center (5)
What is being tested here
Drugs under test in Testicular Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Paclitaxel | 1 | 3 | 15 |
| AMG 757 | 1 | 0 | 1 |
| Aspirin | 1 | 0 | 1 |
| Brodalumab | 1 | 0 | 1 |
| Methadone | 1 | 1 | 1 |
| Anti-IGSF8 Monoclonal Antibody GV20-0251 | 1 | 0 | 1 |
| Carboplatin | 0 | 1 | 19 |
| Etoposide | 0 | 3 | 19 |
| Ifosfamide | 0 | 2 | 16 |
| Cisplatin | 0 | 2 | 9 |
Drug classes tested here Antimitotic agents 1 open · Alkylating agents 28 · Antimetabolites 9 · Immune checkpoint inhibitors 5 · Tyrosine kinase inhibitors (TKIs) 5
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Dec 2026Intrathecal Morphine Versus Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection. · Phase 3 · Indiana University
- May 2027Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer · Phase 3 · St. Olavs Hospital
- Dec 2026WATChmAN Virtual Testicular Cancer Clinic · University Health Network, Toronto
- Dec 2026Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors · Fudan University
- Dec 2026Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors · University of Southern California
- Dec 2026Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma · Swiss Cancer Institute
- Dec 2026MicroRNA as Markers in Testicular Cancer · Haukeland University Hospital
- Jan 2027Lymphedema After Urologic Surgery · Vastra Gotaland Region
- Jan 2027A Study of miRNA 371 in Patients With Germ Cell Tumors · SWOG Cancer Research Network
- Feb 2027miRNA to Guide Appropriate Intervention of Small Testis Masses · University Health Network, Toronto
Who these studies take
Of the 43 Testicular Neoplasms studies recruiting now, 26 (60%) set no upper age limit and 11 (26%) stop at 75 or younger. 6 (14%) take children under 18. 0 (0%) are for women only and 21 (49%) for men only; 4 (9%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 3 (7%) | 4 (9%) |
| 18 | 20 (47%) | 41 (95%) |
| 30 | 21 (49%) | 42 (98%) |
| 40 | 19 (44%) | 39 (91%) |
| 50 | 17 (40%) | 37 (86%) |
| 65 | 17 (40%) | 36 (84%) |
| 75 | 15 (35%) | 33 (77%) |
| 85 | 14 (33%) | 31 (72%) |
Across all 295 studies, recruiting or not: 34% stop at 75 or younger and 27% at 65; 38% take children; 0% are for women only and 38% for men only; 8% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Testicular Neoplasms studies take
Of 17 phase 2 interventional studies under Testicular Neoplasms, half reached primary completion within 51 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 2 | 51 mo38–83 · 17 studies | — | — |
| Interventional, no phase | 33 mo11–72 · 31 studies | — | — |
| Observational | 63 mo34–191 · 41 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
Studies
Recruiting first, then most recently updated. Showing 50 of 295. Browse all 295 → or search them.
- Virtual Testis Cancer Lay Support and Survivorship Aim 2Not yet recruitingNCT06702592Not applicable1 country
- Patient Reported Experiences With Sparing External Oblique Fascia Vs Standard Inguinal OrchiectomyRecruitingNCT06828185Not applicable1 country
- A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid TumorsRecruitingNCT06515613Phase 12 countries
- Germ Cell Tumor and Testicular Tumor DNA RegistryRecruitingNCT020997341 country
- Late Subclinical Cardiovascular Disease in Testicular Cancer SurvivorsRecruitingNCT056113071 country
- MAGESTIC Trial: MiRNA in Detecting Active Germ Cell Tumors in Early Suspected and MetastaTIC Disease TrialRecruitingNCT060608732 countries
- Paclitaxel-Bleomycin/Etoposide/Cisplatin vs Bleomycin/Etoposide/Cisplatin in Poor-prognosis Non-seminomatous Germ Cell Tumors (NSGCT) and Unfavorable Tumor Marker DeclineRecruitingNCT07847190Phase 21 country
- Personalized Cancer Support (Thrive Track) to Manage the Emotional Needs of Young Adults With Thyroid, Melanoma and Testicular Cancer, PerCS-YA TrialNot yet recruitingNCT07529080Not applicable1 country
- Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid TumorsRecruitingNCT06276491Phase 16 countries
- Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing TumorsRecruitingNCT06814496Phase 1/21 country
- miRNA to Guide Appropriate Intervention of Small Testis MassesRecruitingNCT078528711 country
- DESTINY-PANTUMOUR04RecruitingNCT071240001 country
- Safety and Diagnostic Performance of 111In-TJD-31 SPECT Imaging in Patients With Solid TumorsNot yet recruitingNCT07815951Phase 11 country
- A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving ChemotherapyRecruitingNCT06866964Phase 21 country
- The TASTY-steering StudyRecruitingNCT07258563Not applicable1 country
- Minimally-invasive ICG-guided Retroperitoneal Sentinel Lymph Node Dissection in the Primary Staging of Testicular Cancer Versus Standard of CareNot yet recruitingNCT07699640Not applicable2 countries
- Navigation Intervention for Adolescent and Young Adult Cancer SurvivorsRecruitingNCT07406087Not applicable1 country
- Integrated Cancer Repository for Cancer ResearchRecruitingNCT020126991 country
- Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)RecruitingNCT07407582Phase 1/21 country
- Brodalumab in the Treatment of Immune-Related Adverse EventsRecruitingNCT06673329Phase 11 country
- Helping Young People With Testicular Cancer Using Virtual and Extended RealityNot yet recruitingNCT07571499Not applicable
- Digital Peer Navigation for Adolescents and Young Adults With CancerRecruitingNCT06193369Not applicable1 country
- Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell TumorsRecruitingNCT07218913Phase 11 country
- Impact of a Physical Activity Program to Reduce Long-term Cancer-related Fatigue in Metastatic Testicular Germ Cell Tumor PatientsRecruitingNCT05588700Not applicable1 country
- Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular CancerRecruitingNCT07498959Not applicable1 country
- Evaluation of Bile Acid Concentrations and Their Signaling as Markers of Testicular Tumorigenesis and Germ Cell Tumor ChemosensitivityRecruitingNCT07463508Not applicable1 country
- Intrathecal Morphine Versus Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection.RecruitingNCT06593665Phase 31 country
- Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer SurvivorsRecruitingNCT06371768Not applicable1 country
- Lymphedema After Urologic SurgeryRecruitingNCT052643371 country
- Swiss Austrian German Testicular Cancer Cohort Study - SAG TCCSRecruitingNCT022299161 country
- A Study of GV20-0251 in Advanced or Refractory Solid TumorsRecruitingNCT07106827Phase 11 country
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruitingNCT034527742 countries
- A Clinical Trial of Primary Retroperitoneal Lymph Node Dissection in Patients With Testicular Seminoma With Limited Retroperitoneal MetastasesRecruitingNCT06932458Phase 21 country
- Voiding and Erectile Function After Retroperitoneal Lymph Node Dissection for Testicular CancerRecruitingNCT069542331 country
- Early Ageing During Therapy in AYA Cancer PatientsRecruitingNCT050627071 country
- A Biobehavioral Intervention to Reduce Adverse Outcomes in Young Adult Testicular Cancer SurvivorsRecruitingNCT05836688Not applicable1 country
- Twenty Years' Experience in Retroperitoneal Lymph Node Dissection for Testicular Cancer in a Tertiary Referral CenterRecruitingNCT068069171 country
- Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced TumorsRecruitingNCT06684327Phase 21 country
- Senescence and the Early Ageing Phenotype After Chemotherapy for Testicular Cancer: the SEA-CAT StudyRecruitingNCT04113122Not applicable1 country
- Circulating microRNAs in Small Testicular Masses and Retroperitoneal Post-chemotherapy Residual Masses.RecruitingNCT066200161 country
- Prospective Observational Study on SEBBIN Silicone Gel-filled Testicular ImplantsRecruitingNCT050978201 country
- CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid TumorsRecruitingNCT05410717Phase 11 country
- The Man Van ProjectRecruitingNCT06357416Not applicable1 country
- Study on the Quality of Life and Functional/Oncological Outcome of Testicular Cancer PatientsRecruitingNCT063894091 country
- Role of Elastography in Diagnosis of Testicular TumorsNot yet recruitingNCT06231329
- WEST-KOaST Study: WES Analysis of Testicular Cancer Patientsand Their First-degree Family MembersNot yet recruitingNCT06142500Not applicable
- Unveiling Patient Experiences in Testicular Cancer Clinical TrialsNot yet recruitingNCT059283771 country
- Investigating Cognitive Impairment in Young Patients With Cancer ProspectivelyRecruitingNCT058405751 country
- Follow-up After Surgery for Testicular CancerRecruitingNCT056709381 country
- MicroRNA as Markers in Testicular CancerRecruitingNCT049140262 countries